The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume. However, the impact of the pretreatme...

Full description

Bibliographic Details
Main Authors: Ken Ohara, Takahiro Masuda, Masato Morinari, Mari Okada, Atsushi Miki, Saki Nakagawa, Takuya Murakami, Kentaro Oka, Maki Asakura, Yasuharu Miyazawa, Akito Maeshima, Tetsu Akimoto, Osamu Saito, Daisuke Nagata
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Diabetology & Metabolic Syndrome
Subjects:
SGLT2 inhibition
Bioimpedance analysis
Heart failure
BNP
Extracellular volume expansion
Hypovolemia
Online Access:http://link.springer.com/article/10.1186/s13098-020-00545-z

Internet

http://link.springer.com/article/10.1186/s13098-020-00545-z

Similar Items